Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

The foot in diabetes – a reminder of an ever-present risk

Sarah Craus, Abigail Mula and David V Coppini
Download PDF
DOI: https://doi.org/10.7861/clinmed2022-0489
Clin Med May 2023
Sarah Craus
AMater Dei Hospital, Msida, Malta
Roles: higher specialist trainee in diabetes and endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: crausarah@gmail.com
Abigail Mula
AMater Dei Hospital, Msida, Malta
Roles: higher specialist trainee in diabetes and endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David V Coppini
BUniversity Hospitals Dorset NHS Trust, Dorset, UK, and visiting fellow, Bournemouth University, Bournemouth, UK
Roles: honorary consultant diabetologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

The term ‘diabetic foot disease’ (DFD) often signifies the presence of foot ulceration and infection, but one must also be wary of the rarer occurrence of Charcot foot disease. The worldwide prevalence of DFD is 6.3% (95%CI: 5.4–7.3%). Foot complications present a major challenge to both patients and healthcare systems, with increased rates of hospitalisation and an almost trebled 5-year mortality. The Charcot foot often occurs in patients with long-standing diabetes, presenting as an inflamed or swollen foot or ankle, following unrecognised minor trauma. This review focuses on the prevention and early identification of the ‘at-risk’ foot. DFD is best managed by a multi-disciplinary foot clinic team consisting of podiatrists and healthcare professionals. This ensures a combination of expertise and provision of a multi-faceted evidence-based treatment plan. Current research using endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) offers a new dimension in wound management.

KEYWORDS
  • Diabetic foot disease
  • infections
  • prevention

Introduction

The global burden of diabetes mellitus and diabetic foot disease (DFD) is exponentially increasing with life expectancy.1,2 Diabetic foot problems are most commonly seen in patients with long-standing and inadequately controlled diabetes.3 These complications negatively impact on patients' quality of life as well as on their socio-economic wellbeing.4 Patients with foot ulcers have an almost three-fold increased risk of death at 5 years compared to those without foot complications.5 Studies also show that dialysis-dependent patients with amputations have a 5-year mortality risk of more than 70%.6

Epidemiology and pathophysiology

A meta-analysis by Zhang et al1 showed that the global prevalence of diabetic foot complications is 6.3% (95%CI: 5.4–7.3%). Males have a higher prevalence rate of DFD than females7–9 (4.5%, 95%CI: 3.7–5.2% vs 3.5%, 95%CI: 2.8–4.2%). The prevalence of DFD at GP practices in the UK in 2008 was estimated at 7.6% (95% CI: 6.6–8.6) for people with type 1 diabetes and 8.5% (95% CI: 8.2–8.8) for those with type 2 diabetes.10

Foot complications are commoner in patients of African or Native-American descent and these patients tend to have longer hospital stays with adverse outcomes.11 Diminished bioavailability of nitric oxide and impaired endothelium-dependent vasodilatation are postulated mechanisms for worse outcomes in these patients when compared to White patients.12

Various factors, including impaired sensation related to neuropathy, abnormal gait and the presence of ischaemia due to peripheral artery disease (PAD), contribute to the development of DFD.13,14 Sensory neuropathy predisposes to repeated microtrauma, callus formation and subcutaneous haemorrhage, leading to skin ulceration.15,16 The exact prevalence of Charcot arthropathy remains unknown, partly because of a lack of standardised diagnostic criteria. One study looked at point prevalence in the East Midlands' secondary care services over a 1-month period. Ninety cases were found, representing 4.3 per 10,000 of the 205,033 persons with diabetes.17

Diabetic foot ulceration (DFU) increases the rates of hospital admissions and is still the commonest cause of non-traumatic lower extremity amputation in the developed world.18 Foot ulceration is a major cause of psychosocial distress.19 The European Study Group on Diabetes and the Lower Extremity (Eurodiale) study recruited patients with a new foot ulcer. This was a prospective observational study. 18% of these subjects underwent a minor amputation while 5% of subjects required a major amputation within 1 year of follow up.20 Male patients are also more likely to undergo amputations at a younger age.21–23 Such differences may be secondary to variations in personal hygiene, self-examination and walking patterns (eg walking barefoot).24,25

Diabetic neuropathy occurs in 30–50% of patients with long-standing diabetes.26–29 The imbalance between mitochondrial and cytosolic reactive oxygen species in patients with vascular problems can lead to axonal nerve damage with progressive distal-to-proximal sensory loss.30,31 In unmyelinated small C fibres, this imbalance can result in painful diabetic neuropathy32,33 and this can sometimes be difficult to distinguish from ischaemic pain. In the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) study, diabetic neuropathy was already present in 6% of patients with type 1 diabetes at the time of diagnosis, increasing to 30% after 13 years of follow up.34,35 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and the Veteran Affairs Diabetes Trial (VADT) showed that neuropathy affects 42% of patients with type 2 diabetes at diagnosis.36,37 Hypertension, dyslipidaemia, and impaired glucose regulation have all been implicated in both the aetiology and progression of diabetic neuropathy.38,39

Sensory neuropathy and abnormal vascularity, as well as external factors such as callus formation and abnormal foot pressures, hamper wound healing. Wound healing involves a synchronous process of coagulation, inflammation, cell migration and proliferation, with extracellular matrix (ECM) deposition.40 This is normally followed by re-epithelisation and a return of tissue function. Growth factors such as platelet-derived growth factor (PDGF), transforming growth factor (TGF) β1 and tissue plasminogen activator (TPA) are all involved in wound healing and ECM deposition. In patients with diabetes, wounds may abnormally stall in some phases of healing41,42 due to the body's inability to recruit cells and re-build tissue within the damaged area.43 Defective angiogenesis also plays a role in the aetiology of the microvascular and macrovascular complications of diabetes. Excessive reactive oxygen species result in instability of the extracellular matrix and altered Vascular Endothelial Growth Factor (VEGF) sensitivity, leading to inadequate vascularity and abnormal healing.41,44,45

Risk assessment, prevention and management

Regular foot inspection enables early recognition of skin damage such as callus formation, blistering or haemorrhage, all of which are strong predictors of ulceration.46–49 Patients with callus formation have an 11-fold increased risk of diabetic foot ulceration compared to those without.50 Both patients and healthcare professionals should be educated on recognising early warning signs of foot ulceration (pedal skin dryness, hyperkeratosis and callus formation) with prompt specialist podiatric referral where necessary. At-risk patients can be prescribed urea-based emollients that help reduce epidermal thickness and also have antimicrobial properties.51,52

Frequency of foot screening depends on loss of protective sensation (LOPS) and ulceration risk in accordance with the International Working Group on the Diabetic Foot (IWGDF) 2019 Risk Stratification System3 (Table 1), but in the general diabetes population, annual screening usually suffices. Once diabetic neuropathy has developed, further screening visits are not necessary, and the patient should be reviewed regularly in a foot protection programme.

View this table:
  • View inline
  • View popup
Table 1.

IWGDF 2019 Risk Stratification System3

Tactile sensation assessed by means of a 10 g Semmes Weinstein monofilament, and vibration sensation using a neurothesiometer, are both useful in assessing risk of foot ulceration.53–55 The neurothesiometer has a handheld probe, which is applied to the great toe and the stimulus is gradually increased until the patient can feel the vibratory sensation.56,57 This measurement is recorded in Volts as a vibration perception threshold (VPT). Vascular status can be carried out at the bedside by clinical palpation of pedal pulses, or more formally using an ultrasound doppler. The VibraScan is a recently developed software-based tool which uses artificial intelligence to measure VPT and can provide information about the extent of diabetic neuropathy with reliable accuracy.57

PAD is an independent risk factor for non-healing ulceration, infection and amputation.58 Patients should also be asked about claudication pain, previous foot ulcers and amputations. The IWGDF recommends that revascularisation is indicated for toe pressures <30 mmHg, for a transcutaneous oxygen pressure (TcpO2) <25 mmHg, or if there is significant tissue loss or infection.3 Revascularisation within 8 weeks using percutaneous transluminal angioplasty (PTA) or bypass surgery restores blood flow to the foot arteries, perfusing the wound area, and reducing amputation risk. Similar outcomes for amputation-free survival (AFS) and overall survival (OS) were observed in patients who undergo angioplasty or bypass for infra-inguinal vascular disease. However, patients who survive for at least 2 years after bypass surgery seem to have better OS and slightly better AFS.59,60 Anti-platelet and lipid-lowering agents also help reduce the progression of established PAD.61 The Diabetes Study of Northern California (DISTANCE), a10-year follow up study established hypertriglyceridemia as an independent marker for lower-extremity amputations.62

Prompt diagnosis of Charcot foot is crucial to successful management. Studies have shown that a delayed diagnosis can lead to additional damage, ulceration and an increased risk of fracture.62–64 The Charcot foot is classically characterised by four stages: inflammation, fragmentation, coalescence and consolidation. In the acute stage, it may be easily mistaken for cellulitis as it often presents as a warm, red, swollen foot which may also be painful. Usually, there are no changes on plain radiograph,65 and magnetic resonance (MR) scanning is often required to help make a diagnosis. Early offloading and immobilisation is the mainstay of treatment in the acute stage.66 This can be achieved by wearing of devices such as total contact casts and DARCO boots.3,5,67–71

Surgical interventions such as osteotomy, flexor tenotomy and Achilles tendon lengthening may be considered in patients who develop foot deformities such as hammer toes and prominent metatarsal heads.72–75

There is a general consensus that patients with diabetes and peripheral artery disease should receive anti-platelet therapy.76 In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, which enrolled 27,395 patients with stable coronary and/or peripheral artery disease, low dose anti-thrombotic therapy (rivaroxaban 2.5 mg twice a day in combination with aspirin 100 mg daily) more than halved the risk of major foot complications (including amputations) and reduced both major adverse cardiovascular events (MACE) and overall mortality.77

Although hyperglycaemia impairs wound healing, the role of intensive glucose control is still being studied.78 In one study by Xiang et al, rates of wound healing were better in patients with a glycated haemoglobin (HbA1c) of 53–63 mmol/mol.79 Euglycemia is however imperative in the prevention of neuropathy and its consequences in both type 1 (DCCT) and type 2 diabetes (UK Prospective Diabetes Study, UKPDS).80,81

Obesity (defined as a body mass index (BMI) ≥30 kg/m2) is the second most common metabolic risk factor for diabetic foot ulceration, as it increases cardiac workload and impairs tissue perfusion and healing. Interventions targeting obesity are important82 and preliminary studies have shown promising effects of weight loss on improving neuropathy.83–85 Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have become instrumental in reducing both HbA1c and weight in routine clinical practice.86 They also have proven cardioprotective effects.87,88 The impact of GLP1-RAs on PAD is unknown and the ongoing STRIDE (Effects of Semaglutide on Functional Capacity in Patients with Type 2 Diabetes and peripheral artery disease) trial is aimed at investigating a possible effect of semaglutide on walking ability in persons with diabetes and symptomatic PAD.89

Lifestyle interventions including feasible exercise in addition to patient education may play a role in the management of persons with DFD,90–92 but it remains unknown what the exact effect is and which educational approach is most effective.47 It should however account for gender and cultural differences and must be adapted to the patient's level of ability, education and acceptance.93

Dietary factors, mainly protein intake, are important for tissue repair and wound healing. Inadequate protein intake can lead to defective angiogenesis and a poor inflammatory response, resulting in defective wound healing.94,95 A balanced diet that can help address BMI while providing all the necessary nutritional requirements for wound healing is crucial in patients with diabetic foot problems. Patients with a BMI >40 kg/m2 should be considered for bariatric surgery (including Roux-en Y Gastric Bypass or sleeve gastrectomy). Randomised trials by Schauer96et al confirmed a superiority of bariatric surgery over medical treatment on HbA1c, BMI, plasma triglycerides and quality of life (QoL). Other studies have shown partial or complete remission of diabetes following bariatric surgery.97,98 Other adverse factors on wound healing include hypertension, dyslipidaemia, smoking and excessive alcohol intake99,100 and should all be addressed in patients attending the foot clinic.

Diabetic foot ulcers commonly harbour contaminant or colonising pathogens, but these commensals do not usually cause active infection. Purulent secretions, a foul odour and wound undermining are important hallmarks of active infection. New ulcers need to be attended to immediately by the specialist diabetic foot team. Infection inhibits adequate wound healing by releasing bacterial enzymes with subsequent degradation of growth factors and metalloproteinase fibrins.101,102 Deep tissue cultures are preferred to superficial wound swabs as the latter often identify microbial contaminants that may not warrant treatment.71 Tissue probing and radiological investigations (plain radiography, magnetic resonance imaging) are all useful for identifying foreign bodies and diagnosing osteomyelitis (NICE, 2019). Oral broad-spectrum antibiotics are initially prescribed and changed to more specific agents later on, depending on clinical response and wound culture sensitivities. Intravenous antibiotics are often used for more severe infections, particularly those with deep soft tissue and bone involvement. Wounds should be debrided and cleaned of any necrotic material and foreign bodies.20 Debridement is carried out by specialist podiatrists, but deep tissue involvement may require surgical or orthopaedic intervention. Application of appropriate dressings provides an optimum environment for wound healing.103 Dressings are usually selected based on TIMES assessment – Tissue, Infection, Moisture balance, Epithelialisation and surrounding Skin104,105 – and on the healing stage of the wound. These should be regularly inspected and changed, particularly in exudative wounds, in order to reduce maceration of surrounding skin.106

Cell-based therapies, including endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSC), have shown encouraging results, improving pain-free walking distance, ankle-brachial pressure index (ABPI) and tissue oxygenation.107–111 Recombinant growth factors, platelet-rich plasma (PRP) and leukocyte- and platelet-rich fibrin (L-PRF) are also promising new treatment methods that enhance wound healing.111

Another preliminary study recommends the use of stromal vascular fraction (SVF) for chronic diabetic ulcers.112 Although MSC seem to be generally safe, there have been some reports of adverse thrombo-embolic events.113,114 Larger studies will certainly help address their efficacy, safety and optimal administration route.

Conclusion

Successful management of the diabetic foot requires a multidisciplinary team (MDT) approach consisting of specialist podiatrists, orthotists, diabetologists, diabetes nurse specialists and dietitians, as well as vascular and orthopaedic surgeons.

Prevention of foot complications remains key to limb protection and salvage, particularly in vulnerable patients and those with limited access to healthcare. As we care for patients with diabetes, we should certainly remember the still very ubiquitous presence of foot complications in hospitals, care homes and indeed the community. Despite a gargantuan milestone in diabetes care in the last decade, foot ulceration remains a persistent problem for many patients. Continuous education, not only of patients with diabetes but also of healthcare workers within all disciplines remains pivotal in the prevention and early management of this omnipresent and troublesome complication.

Key practice implications

  • Diabetic foot disease remains a common complication in patients with diabetes, with up to a prevalence of 7.6% in the UK.

  • Foot complications still present a major challenge to persons with diabetes and healthcare systems, and are best managed within a multidiscipinary team setting.

  • Education of patients and healthcare professionals across all medical specialties helps to identify and manage diabetic foot complications in a timely manner.

  • Good glycaemic control, management of obesity and lifestyle modifications complement specialist podiatric input in wound prevention and management.

  • Novel therapies with progenitor stem cells open a new horizon in wound management.

  • © Royal College of Physicians 2023. All rights reserved.

References

  1. ↵
    1. Zhang P
    , Lu J, Jing Y, et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Ann Med 2017;49:106–16.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sorber R
    , Abularrage CJ. Diabetic foot ulcers: Epidemiology and the role of multidisciplinary care teams. In: Seminars in vascular surgery (Vol. 34, No. 1, pp. 47–53). WB Saunders; 2021.
    OpenUrl
  3. ↵
    1. Schaper NC
    , Apelqvist J, Bakker K. The international consensus and practical guidelines on the management and prevention of the diabetic foot. Curr Diab Rep 2003;3:475–9.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Yimam A
    , Hailu A, Murugan R, et al. Prevalence of diabetic foot ulcer and associated factors among diabetic patient in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Int J Africa Nurs Sci 2021;14:100285.
    OpenUrl
  5. ↵
    1. Walsh JW
    , Hoffstad OJ, Sullivan MO, et al. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabetes Med 2016;33:1493–8.
    OpenUrlPubMed
  6. ↵
    1. Lavery LA
    , Hunt NA, LaFontaine J, et al. Diabetic foot prevention: a neglected opportunity in high-risk patients. Diabetes Care 2010;33:1460–2.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Abbott CA
    , Carrington AL, Ashe H. The North-West Diabetes Foot Care Study: incidence of, and risk factors for new diabetic foot ulceration in a community-based patient cohort. Diabetes Med 2002;19:377–84.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hicks CW
    , Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J Vasc Surg 2014;60:1247–54.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Zhang B
    , Wang M, Gong A, et al. HucMSC-exosome mediated-Wnt4 signalling is required for cutaneous wound healing. Stem Cells 2015;33:2158–68.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Lauterbach S
    , Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care 2010;19:333–7.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Tan TW
    , Armstrong DG, Concha-Moore KC, et al. Association between race/ethnicity and the risk of amputation of lower extremities among medicare beneficiaries with diabetic foot ulcers and diabetic foot infections. BMJ Open Diabetes Res Care 2020;8:e001328.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kalinowski L
    , Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation 2004;109:2511–7.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Armstrong DG
    , Lavery LA, Van Houtum WH, et al. The impact of gender on amputation. J Foot Ankle Surg 1997;36:66–9.
    OpenUrlPubMed
  14. ↵
    1. Mishra SC
    , Chhatbar KC, Kashikar A, et al. Diabetic foot. BMJ 2017;359:j5064.
    OpenUrlFREE Full Text
  15. ↵
    1. Schaper NC
    , van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev 2020;36:e3266.
    OpenUrl
  16. ↵
    1. Jeffcoate W
    , Game F. The charcot foot reflects a response to injury that is critically distorted by preexisting nerve damage: an imperfect storm. Diabetes Care 2022;45:1691–7.
    OpenUrl
  17. ↵
    1. Metcalf L
    , Musgrove M, Bentley J, et al. Prevalence of active Charcot disease in the East Midlands of England. Diabetes Med 2018;35:1371–4.
    OpenUrl
  18. ↵
    1. Armstrong DG
    , Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician 1998;57:1325–32, 1337–8.
    OpenUrl
  19. ↵
    1. Baig MS
    , Banu A, Zehravi M, et al. An overview of diabetic foot ulcers and associated problems with special emphasis on treatments with antimicrobials. Life 2022;12:1054.
    OpenUrl
  20. ↵
    1. Prompers L
    , Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008;51:747–55.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kiziltan ME
    , Gunduz A, Kiziltan G, et al. Peripheral neuropathy in patients with diabetic foot ulcers: clinical and nerve conduction study. J Neurol Sci 2007;258:75–9.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Peek ME
    . Gender differences in diabetes-related lower extremity amputations. Clin Orthop Relat Res 2011;469:1951–5.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Huang ZH
    , Li SQ, Kou Y, et al. Risk factors for the recurrence of diabetic foot ulcers among diabetic patients: a meta-analysis. Int Wound J 2019;16:1373–82.
    OpenUrl
  24. ↵
    1. Rossaneis MA
    , Haddad MDCFL, Mathias TADF, et al. Differences in foot self-care and lifestyle between men and women with diabetes mellitus. Rev Lat Am Enfermagem 2016;24:e2761.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Jarl G
    , Alnemo J, Tranberg R, et al. Gender differences in attitudes and attributes of people using therapeutic shoes for diabetic foot complications. J Foot Ankle Res 2019;12:21.
    OpenUrl
  26. ↵
    1. Young MJ
    , Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150–4.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Cabezas-Cerrato J
    . The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia 1998;41:1263–9.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Tovi J
    , Svanborg E, Nilsson BY, et al. Diabetic neuropathy in elderly type 2 diabetic patients: effects of insulin treatment. Acta Neurol Scand 1998;98:346–53.
    OpenUrlPubMed
  29. ↵
    1. Feldman EL
    , Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers 2019;5:42.
    OpenUrl
  30. ↵
    1. Feldman EL
    , Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 2017;93:1296–313.
    OpenUrlPubMed
  31. ↵
    1. Sajic M
    . Mitochondrial dynamics in peripheral neuropathies. Antioxid Redox Signal 2014;21:601–20.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Green AQ
    , Krishnan S, Finucane FM, et al. Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care 2010;33:174–6.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Hicks CW
    , Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 2019;19:86.
    OpenUrlPubMed
  34. ↵
    1. Albers JW
    , Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090–6.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Martin CL
    , Albers JW, Pop-Busui R, et al. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:31–8.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Duckworth W
    , Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Ismail-Beigi F
    , Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419–30.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Lupachyk S
    , Watcho P, Hasanova N, et al. Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress. Free Radic Biol Med 2012;52:1255–63.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Callaghan BC
    , Feldman EL. Painful diabetic neuropathy: many similarly effective therapies with widely dissimilar costs. Ann Intern Med 2014;161:674–5.
    OpenUrl
  40. ↵
    1. Falanga V
    . Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736–43.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Loots MA
    , Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998;111:850–7.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Loots MA
    , Kenter SB, Au FL, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002;81:153–60.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Anderson JJ
    , Hansen M, Rowe GP, et al. Complication rates in diabetics with first metatarsophalangeal joint arthrodesis. Diabet Foot Ankle 2014;5:24649.
    OpenUrl
  44. ↵
    1. Tchaikovski V
    , Olieslagers S, Böhmer FD, et al. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009;120:150–59.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Vuorisalo S
    , Venermo M, Lepäntalo M. Treatment of diabetic foot ulcers. J Cardiovasc Surg 2009;50:275.
    OpenUrlPubMed
  46. ↵
    1. Dubský M
    , Jirkovská A, Bem R, et al. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. Int Wound J 2013;10:555–61.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Bus SA
    , Lavery LA, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020;36:e3269.
    OpenUrl
  48. ↵
    1. Miranda C
    , Da Ros R, Marfella R. Update on prevention of diabetic foot ulcer. Arch Med Sci Atheroscler Dis 2021;6:123–31.
    OpenUrl
  49. ↵
    1. Waaijman R
    , De Haart M, Arts ML, et al. Risk factors for plantar foot ulcer recurrence in neuropathic diabetic patients. Diabetes Care 2014;37:1697–705.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Murray HJ
    , Young MJ, Hollis S, et al. The association between callus formation, high pressures and neuropathy in diabetic foot ulceration. Diabet Med 1996;13:979–82.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Grether-Beck S
    , Felsner I, Brenden H, et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol 2012;132:1561–72.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Bristow I
    . Emollients in the care of the diabetic foot. Diabet Foot 2013;16:63–6.
    OpenUrl
  53. ↵
    1. Coppini DV
    , Spruce MC, Thomas P, et al. Established diabetic neuropathy seems irreversible despite improvements in metabolic and vascular risk markers—a retrospective case–control study in a hospital patient cohort. Diabet Med 2006;23:1016–20.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Frade MAC
    , Bernardes Filho F, Silva CML, et al. Evaluation of altered patterns of tactile sensation in the diagnosis and monitoring of leprosy using the Semmes-Weinstein monofilaments. Plos One 2022;17:e0272151.
    OpenUrl
  55. ↵
    1. Nakamoto M
    , Ideguchi N, Iwata S, et al. Validity and Reliability of Criteria for Plantar Sensation Assessment Using Semmes–Weinstein Monofilament as a Clinically Usable Index. Int J Environ Res Public Health 2022;19:14092.
    OpenUrl
  56. ↵
    1. Garrow AP
    , Boulton AJ. Vibration perception threshold—a valuable assessment of neural dysfunction in people with diabetes. Diabetes Metab Res Rev 2006;22:411–19.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Dubey VN
    , Dave JM, Beavis J, et al. Predicting Diabetic Neuropathy Risk Level Using Artificial Neural Network and Clinical Parameters of Subjects With Diabetes. J Diabetes Sci Technol 2022;16:275–81.
    OpenUrl
  58. ↵
    1. Ward R
    , Dunn J, Clavijo L, et al. Outcomes of critical limb ischemia in an urban, safety net hospital population with high WIfI amputation scores. Ann Vasc Surg 2017;38:84–9.
    OpenUrl
  59. ↵
    1. Bradbury AW
    , Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 2010;51:5S–17S.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Elgzyri T
    , Larsson J, Nyberg P, et al. Early revascularization after admittance to a diabetic foot center affects the healing probability of ischemic foot ulcer in patients with diabetes. Eur J Vasc Endovascular Surg 2014;48:440–6.
    OpenUrl
  61. ↵
    1. Donnelly R
    , Yeung JMC. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovascular Surg 2002;23:100–7.
    OpenUrl
  62. ↵
    1. Callaghan BC
    , Feldman E, Liu J, et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 2011;34:635–40.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Foltz KD
    , Fallat LM, Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. J Foot Ankle Surg 2004;43:87–92.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Frykberg RG
    , Belczyk R. Epidemiology of the Charcot foot. Clin Podiatr Med Surg 2008;25:17–28.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Wukich DK
    , Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 2009;23:409–26.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Holmes C
    , Schmidt B, Munson M, et al. Charcot stage 0: A review and considerations for making the correct diagnosis early. Clin Diabetes Endocrinol 2015;1:18.
    OpenUrl
  67. ↵
    1. Racaru S
    , Saghdaoui LB, Choudhury JR, et al. Offloading treatment in people with diabetic foot disease: A systematic scoping review on adherence to foot offloading. Diabetes Metab Syndr 2022;16:102493.
    OpenUrl
  68. ↵
    1. Healy A
    , Naemi R, Chockalingam N. The effectiveness of footwear as an intervention to prevent or to reduce biomechanical risk factors associated with diabetic foot ulceration: a systematic review. J Diabetes Complications 2013;27:391–400.
    OpenUrl
  69. ↵
    1. Premkumar R
    , Rajan P, Rima J, et al. Footwear in the causation and prevention of foot ulcers in diabetes mellitus. Natl Med J India 2017;30:255–61.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Margolis DJ
    , Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 2000;136:1531–35.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Cavanagh PR
    , Lipsky BA, Bradbury AW, et al. Treatment for diabetic foot ulcers. Lancet 2005;366:1725–35.
    OpenUrlCrossRefPubMed
  72. ↵
    1. O'Brien JF
    , Grace PA, Perry IJ, et al. Randomized clinical trial and economic analysis of four-layer compression bandaging for venous ulcers. Br J Surg 2003;90:794–8.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Armstrong DG
    , Lavery LA, Frykberg RG, et al. Validation of a diabetic foot surgery classification. Int Wound J 2006;3:240–6.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Frykberg RG
    , Bevilacqua NJ, Habershaw G. Surgical off-loading of the diabetic foot. J Am Podiatr Med Assoc 2010;100:369–84.
    OpenUrlPubMed
  75. ↵
    1. Rasmussen A
    , Bjerre-Christensen U, Almdal TP, et al. Percutaneous flexor tenotomy for preventing and treating toe ulcers in people with diabetes mellitus. J Tissue Viability 2013;22:68–73.
    OpenUrlCrossRefPubMed
  76. ↵
    1. van Netten JJ
    , Bril A, van Baal JG. The effect of flexor tenotomy on healing and prevention of neuropathic diabetic foot ulcers on the distal end of the toe. J Foot Ankle Res 2013;6:3.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Cosentino F
    , Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255–323.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Anand SS
    , Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219–29.
    OpenUrlPubMed
  79. ↵
    1. Rastogi A
    , Mukhopadhyay S, Sahoo JP, et al. Intensive glycemic control for diabetic foot ulcer healing: a multicentric, randomized, parallel arm, single-blind, controlled study protocol (INGLOBE study). Int J Low Extrem Wounds 2022;21:443–9.
    OpenUrl
  80. ↵
    1. Xiang J
    , Wang S, He Y, et al. Reasonable Glycemic Control Would Help Wound Healing During the Treatment of Diabetic Foot Ulcers. Diabetes Ther 2019;10:95–105.
    OpenUrl
  81. ↵
    1. DCCT Research Group
    . Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450–9.
    OpenUrlCrossRefPubMed
  82. ↵
    1. King P
    , Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999;48:643–8.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Callaghan BC
    , Gallagher G, Fridman V, et al. Diabetic neuropathy: what does the future hold? Diabetologia 2020;63:891–7.
    OpenUrl
  84. ↵
    1. Balducci S
    , Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications 2006;20:216–23.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Smith AG
    , Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006;29:1294–9.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Liarakos AL
    , Tentolouris A, Kokkinos A, et al. Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. J Diabetes Complications 2023;37:108390.
    OpenUrl
  87. ↵
    1. Kluding PM
    , Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 2012;26:424–9.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Davies MJ
    , Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753–86.
    OpenUrlCrossRef
  89. ↵
    1. Wan W
    , Qin Q, Xie L, et al. GLP-1R signaling and functional molecules in incretin therapy. Molecules 2023;28:751.
    OpenUrl
  90. ↵
    1. Lim R
    , Malhotra A, Tan J, et al. First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med 2018;7:628–35.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Perrin BM
    , Southon J, McCaig J, et al. The effect of structured exercise compared with education on neuropathic signs and symptoms in people at risk of neuropathic diabetic foot ulcers: A randomized clinical trial. Medicina 2021;58:59.
    OpenUrl
  92. ↵
    1. Appil R
    , Sjattar EL, Yusuf S, et al. Effect of family empowerment on HbA1c levels and healing of diabetic foot ulcers. Int J Low Extrem Wounds 2022;21:154–60.
    OpenUrl
  93. ↵
    1. Singleton JR
    , Marcus RL, Lessard MK, et al. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol 2015;77:146–53.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Vas PR
    , Edmonds ME, Papanas N. Nutritional supplementation for diabetic foot ulcers: the big challenge. Int J Low Extrem Wounds 2017;16:226–9.
    OpenUrl
  95. ↵
    1. Sajid N
    , Miyan Z, Zaidi SIH, et al. Protein requirement and its intake in subjects with diabetic foot ulcers at a tertiary care hospital. Pak J Med Sci 2018;34:886–90.
    OpenUrl
  96. ↵
    1. Schauer PR
    , Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 2014;370:2002–13.
    OpenUrlCrossRefPubMed
  97. ↵
    1. Yan Y
    , Sha Y, Yao G, et al. Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine 2016;95:e3462.
    OpenUrlCrossRef
  98. ↵
    1. Deshpande AD
    , Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254–64.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Guo JJ
    , Yang H, Qian H, et al. The effects of different nutritional measurements on delayed wound healing after hip fracture in the elderly. J Surg Res 2010;159:503–8.
    OpenUrlCrossRefPubMed
  100. ↵
    1. Musa HG
    , Ahmed ME. Associated risk factors and management of chronic diabetic foot ulcers exceeding 6 months' duration. Diabet Foot Ankle 2012;3:18980.
    OpenUrl
  101. ↵
    1. Everett E
    , Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci 2018;1411:153–65.
    OpenUrl
  102. ↵
    1. Jones V
    . Selecting a dressing for the diabetic foot: factors to consider. Diabetic Foot 1998;1:48–54.
    OpenUrl
  103. ↵
    1. Finlayson K
    , Miaskowski C, Alexander K, et al. Distinct wound healing and quality-of-life outcomes in subgroups of patients with venous leg ulcers with different symptom cluster experiences. J Pain Symptom Manage 2017;53:871–9.
    OpenUrl
  104. ↵
    1. Alves P
    , Manuel T, Mendes N, et al. Dressing selection challenges in diabetic foot local treatment. In: The Science, Etiology and Mechanobiology of Diabetes and its Complications. Academic Press; 2021:389–405.
  105. ↵
    1. Armstrong DG
    , Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–75.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Nazari-Shafti TZ
    , Neuber S, Garcia Duran A, et al. Human mesenchymal stromal cells and derived extracellular vesicles: Translational strategies to increase their proangiogenic potential for the treatment of cardiovascular disease. Stem Cells Transl Med 2020;9:1558–69.
    OpenUrl
  107. ↵
    1. Franz RW
    , Shah KJ, Pin RH, et al. Autologous bone marrow mononuclear cell implantation therapy is an effective limb salvage strategy for patients with severe peripheral arterial disease. J Vasc Surg 2015;62:673–80.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Das AK
    , Abdullah BJJB, Dhillon SS, et al. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study. World J Surg 2013;37:915–22.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Bura A
    , Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014;16:245–57.
    OpenUrlCrossRefPubMed
  110. ↵
    1. Lopes L
    , Setia O, Aurshina A, et al. Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther 2018;9:188.
    OpenUrl
  111. ↵
    1. Uzun E
    , Güney A, Gönen ZB, et al. Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study. Foot Ankle Surg 2021;27:636–42.
    OpenUrl
  112. ↵
    1. Carstens MH
    , Quintana FJ, Calderwood ST, et al. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med 2021;10:1138–47.
    OpenUrl
  113. ↵
    1. Jung JW
    , Kwon M, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013;54:1293–6.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Tatsumi K
    , Ohashi K, Matsubara Y, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 2013;431:203–9.
    OpenUrlPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The foot in diabetes – a reminder of an ever-present risk
Sarah Craus, Abigail Mula, David V Coppini
Clinical Medicine May 2023, 23 (3) 228-233; DOI: 10.7861/clinmed2022-0489

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The foot in diabetes – a reminder of an ever-present risk
Sarah Craus, Abigail Mula, David V Coppini
Clinical Medicine May 2023, 23 (3) 228-233; DOI: 10.7861/clinmed2022-0489
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Epidemiology and pathophysiology
    • Risk assessment, prevention and management
    • Conclusion
    • Key practice implications
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • How to approach acute thrombosis and thrombocytopenia
  • Posterior circulation ischaemic stroke diagnosis and management
Show more Review

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians